Prevalence of Conjunctivitis and Indentification of Risk Factors With and Without Prophylactic Antibiotic Treatment in Neonates
Completed
- Conditions
- Ophthalmia Neonatorum
- Interventions
- Other: whithout Rifamycine treatmentOther: Rifamycine treatment
- Registration Number
- NCT03528915
- Lead Sponsor
- Centre Hospitalier Universitaire, Amiens
- Brief Summary
The French guidelines for the use of Rifamycine eye drops in delivery room to prevent neonatal conjunctivitis have been actualized. Only newborns exposed to risk factors of conjunctivitis should be treated, compared to previous guidelines, treating all newborns. currently, there are no data describing risk factors for neonatal conjunctivitis. This study evaluated the incidence of conjunctivitis with or without Rifamycine eye drops treatment in the delivery room. Then risk factors for neonatal conjunctivitis where analyzed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 881
Inclusion Criteria
- Newborns at the University Hospital of Amiens> 36SA,
- Admitted in maternity at the exit of nursery
Exclusion Criteria
- Newborns at the Amiens University Hospital <36SA
- Eye drops for any medical reason within the first day of life.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description no-antibiotic group whithout Rifamycine treatment Newborns not treated with antibiotic prophylaxis in a systemic way, according to the new french guidelines of January 1st, 2015. Prophylaxis group Rifamycine treatment Newborns treated with rifamycin eye drops systemically two months before change of practices in delivery room.
- Primary Outcome Measures
Name Time Method Occurrence of conjunctivitis during the first 8 days of life in newborns 8 days
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
CHU Amiens-Picardie
🇫🇷Amiens, France